John McCamant

We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects, says John McCamant, editor of Medical Technology Stock Letter.

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver inflammation/NASH, suggests John McCamant, editor of Medical Technology Stock Letter.

The launch of Madrigal Pharmaceuticals Inc.’s (MDGL) NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion. Madrigal has been a long-time top pick, highlights John McCamant, editor of Medical Technology Stock Letter.

The long awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF (XBI) to finally break above the 102-103 level after three or four attempts. Meanwhile, Bicycle Therapeutics Plc (BCYC) had a strong ESMO following promising new data for BT8009, BT5528, and BT7480, explains John McCamant, editor of The Medical Technology Stock Letter.

With hundreds of biotech companies to invest in, stock selection is paramount. In this session John will highlight past biotech winners to help frame current biotech recommendations.